An interventional study of IMMUNOSCORE® in Non Metastatic Colorectal Cancer, sponsored by Hospital St. Joseph, Marseille, France. Recruiting at 2 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-04-13.
Sponsored by Hospital St. Joseph, Marseille, France · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 581 studies in Colorectal Neoplasms with a site in France — 110 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.
Among the 581 studies in Colorectal Neoplasms with a site in France, this one is the 283rd largest by planned enrollment of the 463 interventional ones that give a count, is one of 34 that started in 2022, is one of 116 with no phase, reaches primary completion later than 107 of the 164 other live ones, and was the 418th registered.
6,544 studies on the registry are indexed under Colorectal Neoplasms; 1,666 are open to participants now.
Browse Colorectal Neoplasms studies →110 of the 581 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Antoine Lacassagne · Sites in France
Ages 18–75
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
University Hospital, Caen · Sites in France
Ages 50–75
University Hospital, Bordeaux · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,184 Colorectal Neoplasms studies recruiting now, 767 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 124 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
581 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 116 · Phase 2 206 · Phase 3 97 · Phase 4 6
First in 1993; this study’s year is marked. 34 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 76 across 4,801 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 152 across the 463 interventional studies, 278 across the 102 observational. Of the 356 that completed or were terminated, 105 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
223 of 581 have an industry lead sponsor. The 10 most frequent:
Hospital St. Joseph, Marseille, France is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Hospital St. Joseph, Marseille, France has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520578Phase 3University Hospital, CaenEFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) | 2027-03-24 |
| NCT07361575Clinique Paris-BercyStudy Comparing the Quality of Colon Cleanliness With Prepackaged LRD (Low-residue Diet) vs. Guided (POG). | 2026-11-15 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
Add all 38 to your calendar (.ics) → With an account.
Among the 581 studies in Colorectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Evaluate the patient care recommandation induced by the IMMUNOSCORE® result
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumour. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: IMMUNOSCORE®
recommendation for patient care according to the result of the IMMUNOSCORE®
Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision
Time frame: 5 years
Replication error (RER) phenotype
Number of cases where the Immunoscore® resultat is inconsistent with the RER phenotype
Time frame: 6 and 9 months
KRAS, NRAS and BRAF mutations
Number of cases where the Immunoscore® resultat is inconsistent with the KRAS, NRAS and BRAF mutations
Time frame: 6 and 9 months
Ratio of ciruclating tumor DNA level
Number of cases where the Immunoscore® resultat is inconsistent with the ratio of ciruclating tumor DNA level
Time frame: 6 and 9 months
Actual survival (patient alive without recurrence, alive with recurrence, dead)
Number of cases where the Immunoscore® resultat is inconsistent with the actual survival
Time frame: 5 years
Started Apr 2022 (actual). Primary completion is estimated for Apr 2028, 72 months after the start.
Of 899 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 72 months is above that.
Counting every sponsor, half of 956 studies reached it within 32 months; a quarter within 14 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital St. Joseph, Marseille, France